Bonus BioGroup
Press Room

Press Releases 2020

Press Releases 2020

Press Releases 2020

The success of Bonus BioGroup’s MesenCure in the treatment of acute pneumonia will be presented at the annual meeting of the International Society for Cell & Gene Therapy (ISCT)


Bonus BioGroup (TASE: BONS.TA), a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue engineered and cell therapy products, is pleased to announce that the Company has been invited to present its technological breakthrough in its promising preliminary pre-clinical results of the development of MesenCure, novel, cell-based drug product (hereinafter: "the Study"), developed specifically for the treatment of life-threatening acute respiratory distress in COVID-19 and pneumonia patients, to 1,800 scientists, physicians, and public opinion leaders from around the world, attending the conference of the International Society for Cell & Gene Therapy - "ISCT". The ISCT conference will be held May 28-29, 2020, via video broadcast.

Successful treatment of acute pneumonia, demonstrating that following the administration of MesenCure, the treated lung appeared as a healthy lung


Bonus BioGroup (TASE: BONS.TA), a clinical-stage Israeli biotechnology company engaged in research and development of biomedical tissue engineered and cell therapy products, is pleased to announce the preliminary pre-clinical study results of a novel, unique drug product  MesenCure (hereinafter: "the Study"), developed by the Company specifically for the treatment of life-threatening acute respiratory distress in COVID -19 and pneumonia patients, which has demonstrated the successful treatment of acute pneumonia in an animal model. This success is reflected in the fact that following the treatment with MesenCure, the microscopic appearance of the treated lungs was similar to a healthy lung, and a significant improvement in additional related parameters was achieved.

Bonus BioGroup is pleased to announce that on April 19, 2020, it initiated a preclinical study (“the Study”) of a unique drug product termed MesenCure, specially developed by the Company for the treatment of acute and life-threatening respiratory distress in coronavirus (COVID-19) and pneumonia patients. The drug MesenCure consists of activated Mesenchymal Stromal Cells (“MSCs”) that are isolated from the adipose tissue of healthy donors. The activation of the MSCs before their administration is intended to boost their therapeutic efficacy while maintaining their excellent safety profiles and is achieved by exposing them to an innovative combination of chemical, biological, and physical conditions. Following intravenous transfusion, the activated cells are expected to reach the lungs and act to reduce inflammation, promote the regeneration of the diseased lung tissue, and alleviate respiratory and other symptoms.

Bonus BioGroup is pleased to announce the approval of the European patent by the European Patent Office (EPO), which provides Bonus Therapeutics, a subsidiary of Bonus BioGroup, exclusive protection for the development, utilization and commercialization of Bonus’ live bone graft product in Europe, for the treatment of bone deficiencies (hereafter: “the European patent”), applied by injection or by any other manner.

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy        

© 2020 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.